ADC 下一代 — 载荷创新
zanidatamab 新辅助 · 无化疗 pCR 30%，HER2 下调 56%
This is a breaking report from AACR, one of the world's largest cancer research conferences. The anti-HER2 bispecific antibody zanidatamab has been reported, based on results from the phase 2 NeoZanHER trial, to potentially be effective as neoadjuvant therapy for HER2-positive
热度 7 · 7 赞 · 0 回复 · 0 转发
Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya
读摘要原文 →Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam
读摘要原文 →Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
读摘要原文 →来源：がんナビ通信 · x.com